Mortality and cause of death in mucopolysaccharidosis type II—a historical review based on data from the Hunter Outcome Survey (HOS)Simon Jones, Zsuzsanna Almássy, Michael Beck et al.|Journal of Inherited Metabolic Disease|2009Cited by 183
Agalsidase Alfa and Kidney Dysfunction in Fabry DiseaseMichael L. West, Raphael Schiffmann, William J. Rhead et al.|Journal of the American Society of Nephrology|2009Cited by 162
Substrate reduction therapy in juvenile GM2 gangliosidosisGustavo Maegawa, Joe T.R. Clarke, Brenda Banwell et al.|Molecular Genetics and Metabolism|2009Cited by 69
Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfaRaphael Schiffmann, Pedro E. Huertas, Markus Ries et al.|Genetics in Medicine|2013Cited by 27